Celldex Therapeutics, Inc. (NASDAQ:CLDX) Receives Average Recommendation of "Moderate Buy" from Analysts

Key Points

• Analysts give Celldex a consensus rating of "Moderate Buy" from 12 analysts (2 sell, 1 hold, 8 buy, 1 strong buy) with an average 12‑month target of about $44.45.
• Recent analyst actions are mixed: Goldman Sachs lifted its target to $34 with a neutral rating, Wolfe Research upgraded to outperform with a $44 target, and Stifel reiterated buy while raising its target to $68, while Weiss Ratings remains a sell.
• Fundamentals show a market cap of ~$2.25B and recent shares near $33.86, but Celldex reported a quarterly EPS miss (loss of $1.22 vs. $1.00 expected) and analysts forecast roughly -2.48 EPS for the year.

Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX - Get Free Report) have received a consensus rating of "Moderate Buy" from the twelve analysts that are currently covering the firm, Marketbeat.com reports. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating, eight have assigned a buy rating and one has issued a strong buy rating on the company. The average 12-month target price among brokerages that have issued ratings on the stock in the last year is $44.4545.

CLDX has been the topic of several research analyst reports. The Goldman Sachs Group raised their target price on shares of Celldex Therapeutics from $30.00 to $34.00 and gave the stock a "neutral" rating in a report on Monday, March 2nd. Wolfe Research upgraded shares of Celldex Therapeutics from a "peer perform" rating to an "outperform" rating and set a $44.00 target price on the stock in a report on Monday, March 23rd. Stifel Nicolaus restated a "buy" rating and set a $68.00 target price (up from $58.00) on shares of Celldex Therapeutics in a report on Thursday, February 26th. Finally, Weiss Ratings restated a "sell (d-)" rating on shares of Celldex Therapeutics in a report on Wednesday, January 21st.

Institutional Trading of Celldex Therapeutics

Hedge funds have recently bought and sold shares of the stock. Simplify Asset Management Inc. acquired a new stake in Celldex Therapeutics during the 3rd quarter worth approximately $2,199,000. Segall Bryant & Hamill LLC raised its holdings in Celldex Therapeutics by 36.3% during the 3rd quarter. Segall Bryant & Hamill LLC now owns 528,597 shares of the biopharmaceutical company's stock worth $13,675,000 after buying an additional 140,709 shares during the period. American Century Companies Inc. raised its holdings in Celldex Therapeutics by 4.6% during the 3rd quarter. American Century Companies Inc. now owns 815,560 shares of the biopharmaceutical company's stock worth $21,099,000 after buying an additional 35,575 shares during the period. Propel Bio Management LLC acquired a new stake in shares of Celldex Therapeutics in the third quarter valued at approximately $4,010,000. Finally, Eventide Asset Management LLC raised its holdings in shares of Celldex Therapeutics by 37.1% in the third quarter. Eventide Asset Management LLC now owns 1,859,095 shares of the biopharmaceutical company's stock valued at $48,096,000 after purchasing an additional 502,909 shares during the last quarter.

Celldex Therapeutics Price Performance

Shares of NASDAQ:CLDX opened at $33.86 on Friday. The company has a market capitalization of $2.25 billion, a price-to-earnings ratio of -8.70 and a beta of 1.19. The firm's 50 day simple moving average is $29.11 and its 200 day simple moving average is $27.21. Celldex Therapeutics has a fifty-two week low of $17.59 and a fifty-two week high of $34.52.

Celldex Therapeutics (NASDAQ:CLDX - Get Free Report) last announced its quarterly earnings results on Wednesday, February 25th. The biopharmaceutical company reported ($1.22) earnings per share for the quarter, missing analysts' consensus estimates of ($1.00) by ($0.22). The company had revenue of $0.12 million for the quarter, compared to analyst estimates of $1.53 million. Equities research analysts expect that Celldex Therapeutics will post -2.48 earnings per share for the current year.

About Celldex Therapeutics

Celldex Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted immunotherapies for cancer and other serious diseases. The company's research platforms leverage novel antibody and vaccine technologies designed to engage the patient's immune system, with a particular emphasis on oncology and neurologic indications. Celldex's pipeline includes both monoclonal antibodies and biologic agents that seek to modulate immune responses or deliver targeted cytotoxic activity.

Among Celldex's lead product candidates is glembatumumab vedotin, an antibody–drug conjugate directed against the glycoprotein NMB (gpNMB) for the treatment of certain breast and skin cancers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.